$305.96
▼ -0.0% Today
as of Jul 22, 16:46 ET
Last 30 days
Recent Press Releases & News
BIO: Raising target price to $317.00
BIO: Raising target price to $279.00
Bio-Rad vs. Charles River Labs: Which Medical Research Stock Is a Better Buy in 2026?
Overview
52-week range
$218
$343
70% of range
Avg surprise (last 2)
+41.0%
Avg reaction (last 1)
-1.5%
0% positive
Latest IV / EM
52%
EM ±11.9% · $310 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Mar 31, 2026 | Mar 2026 | $-19.55 | — | — | — | — | financials |
| Tue Sep 30, 2025 | Sep 2025 | $-12.70 | — | — | — | — | financials |
| Thu Jul 31, 2025 | Jun/2025 | $2.61 | $1.93 | +35.2% | — | — | earnings |
| Thu May 1, 2025 | Mar/2025 | $2.54 | $1.73 | +46.8% | — | -1.5% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $23.34 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-76.26 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $13.45 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $3.64 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-39.59 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Jul 30, 2026 | Jun/2026 | OTHER | $2.34 | $2.61 | -10.3% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $592M | — | $653M | $652M | $585M | — | $650M | $638M |
| Cost of revenue | $283M | — | $310M | $306M | $279M | — | $294M | $283M |
| Gross profit | $309M | — | $343M | $345M | $306M | — | $356M | $355M |
| Operating income | $34M | — | $65M | $77M | $24M | — | $64M | $102M |
| Net income | $-527M | — | $-342M | $318M | $64M | — | $653M | $-2.17B |
| EPS (diluted) | $-19.55 | — | $-12.70 | $11.67 | $2.29 | — | $23.34 | $-76.26 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $507M | $530M | $396M | $369M | $521M | $488M | $410M | $407M |
| Inventory | $770M | $741M | $783M | $799M | $790M | $760M | $804M | $804M |
| Total current assets | $2.94B | $2.91B | $2.84B | $2.81B | $3.04B | $3.03B | $3.06B | $3.06B |
| Total assets | $9.79B | $10.58B | $9.70B | $10.21B | $9.53B | $9.36B | $10.60B | $9.69B |
| Long-term debt | $803M | $1.20B | $1.20B | $1.20B | $1.20B | $1.20B | $1.20B | $1.20B |
| Total liabilities | $2.94B | $3.12B | $2.96B | $3.09B | $2.85B | $2.79B | $3.12B | $2.91B |
| Total equity | $6.85B | $7.45B | $6.74B | $7.13B | $6.68B | $6.57B | $7.49B | $6.78B |